Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

549
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
549
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

581
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
581
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

313
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
313
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

104
The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
104
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

963
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
963
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

1.1K
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective epidemiological study in an Aotearoa New Zealand cohort.

The New Zealand medical journal·2026
Same author

A Return to Normality: A Descriptive Qualitative Interview Study Exploring the Patient Experience of Gout Flare Resolution.

Arthritis care & research·2026
Same author

Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system.

Annals of the rheumatic diseases·2026
Same author

Mitonuclear Discordance and Gout, Type 2 Diabetes and Chronic Kidney Disease in Aotearoa New Zealand Indigenous Māori and Pacific People.

Annals of human genetics·2026
Same author

Revisiting the Ethics of Urate-Lowering Therapy Clinical Trials for Gout Management.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Misclassified latent autoimmune diabetes in adults within Māori and Pacific adults with type 2 diabetes in Aotearoa New Zealand.

The New Zealand medical journal·2025
Same journal

Greater trochanteric bursal distension with intra-bursal rice bodies: an unusual MRI presentation.

Joint bone spine·2026
Same journal

Evaluating the Impact of a Rheumatologist-led Comorbidity Review in Patients with Inflammatory Arthritis.

Joint bone spine·2026
Same journal

What cumulative glucocorticoid dose should trigger sparing strategies in polymyalgia rheumatica?

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same journal

Multimodal imaging evaluation of the entheses in spondyloarthritis.

Joint bone spine·2026
Same journal

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. What's new?

Joint bone spine·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.8K

Allopurinol and kidney function: An update.

Lisa K Stamp1, Peter T Chapman2, Suetonia C Palmer3

  • 1Department of Medicine, University of Otago, P.O. Box 4345, Christchurch 8140, New Zealand; Department of Rheumatology, Immunology and Allergy, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand.

Joint Bone Spine
|October 11, 2015
PubMed
Summary
This summary is machine-generated.

Optimal allopurinol dosing for gout patients with chronic kidney disease remains debated. This review examines allopurinol

Keywords:
AllopurinolChronic kidney diseaseGoutKidney functionOxypurinol

More Related Videos

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

1.8K
Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
07:45

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis

Published on: February 9, 2021

4.1K

Related Experiment Videos

Last Updated: Apr 1, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.8K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

1.8K
Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
07:45

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis

Published on: February 9, 2021

4.1K

Area of Science:

  • Nephrology
  • Rheumatology
  • Pharmacology

Background:

  • Gout is prevalent in patients with renal impairment.
  • Allopurinol is a primary urate-lowering therapy.
  • Optimal dosing in chronic kidney disease (CKD) is debated.

Purpose of the Study:

  • To review the relationship between allopurinol and kidney function in adults.
  • To address allopurinol dosing in gout patients with impaired renal function.
  • To explore allopurinol's potential role in CKD without gout.

Main Methods:

  • Literature review of existing studies on allopurinol and kidney function.
  • Analysis of observational data linking serum urate and CKD.
  • Examination of small clinical trials on urate-lowering therapy in CKD.
  • Consideration of allopurinol use in dialysis patients.

Main Results:

  • Ongoing debate exists regarding optimal allopurinol dosing in CKD patients with gout.
  • The effect of allopurinol on CKD progression has shown varying results in small studies.
  • Allopurinol's use in dialysis patients is understudied, requiring careful dose and timing consideration.
  • Emerging evidence suggests a potential role for allopurinol in CKD without gout.

Conclusions:

  • Understanding the interplay between serum urate, kidney function, and allopurinol is crucial for managing gout in CKD.
  • Further research, including larger clinical trials, is needed to clarify allopurinol's role and optimal use in CKD.
  • Careful consideration of dosing and administration timing is essential for allopurinol use in dialysis patients.